Ventyx Biosciences (NASDAQ:VTYX) Earns Neutral Rating from HC Wainwright

Ventyx Biosciences (NASDAQ:VTYX)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports.

Separately, Oppenheimer restated an “outperform” rating and issued a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.00.

Ventyx Biosciences Stock Up 1.0 %

Shares of NASDAQ:VTYX opened at $1.96 on Tuesday. Ventyx Biosciences has a 12-month low of $1.67 and a 12-month high of $11.48. The business has a 50 day moving average of $2.28 and a 200-day moving average of $2.28. The stock has a market cap of $138.59 million, a PE ratio of -0.83 and a beta of 0.55.

Insider Activity

In related news, CEO Raju Mohan purchased 261,752 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were bought at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the completion of the transaction, the chief executive officer now owns 2,175,028 shares of the company’s stock, valued at approximately $4,371,806.28. This trade represents a 13.68 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Sheila Gujrathi acquired 130,000 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average cost of $2.31 per share, with a total value of $300,300.00. Following the transaction, the director now directly owns 130,000 shares of the company’s stock, valued at $300,300. This trade represents a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 630,000 shares of company stock worth $1,262,415. Corporate insiders own 18.18% of the company’s stock.

Hedge Funds Weigh In On Ventyx Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Palumbo Wealth Management LLC bought a new position in Ventyx Biosciences in the third quarter valued at approximately $26,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after purchasing an additional 5,310 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Ventyx Biosciences during the 3rd quarter worth $42,000. The Manufacturers Life Insurance Company raised its holdings in shares of Ventyx Biosciences by 41.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after buying an additional 7,096 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Ventyx Biosciences during the 2nd quarter worth $58,000. 97.88% of the stock is currently owned by institutional investors and hedge funds.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.